Ann: Immutep Investor Update, page-5

Let me translate Marc Voigt's announcement:
- "We feel we've done enough to bring about an infection point, so we ganna sit around and hope something positive happens"

Such a loser approach to doing business!

Here is where Mr Voigt has failed / needs to work on:
- Failed to have the first lag-3 drug to market;
- Failed to develop a robust clinical pipeline that isn't reliant on a single combinable drug (keytruda);
- Failed to create competitive tension amongst big pharma;
- Failed to materialise positive Insight-004 data with Merck Germany into a new collaboration/trial;
- Failed to horizontally expand clinical trials that combine Efti with other suitable drugs (ADC, TIGIT, Other PD-1 drugs);
- Failed to acknowledge that NOVARTIS have made a dogs breakfast of LAG525;
- Failed to acknowledge that GSK are not serious on progressing the out licenced lag3 drugs;

I have to hand it to Marc, Tacti-002 has done well. Efti is derisked, and probably best performing IO combinable drug out there. But enough of the sitting around hoping for the best - go out and hustle!